<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534843</url>
  </required_header>
  <id_info>
    <org_study_id>Chenxp011</org_study_id>
    <nct_id>NCT03534843</nct_id>
  </id_info>
  <brief_title>A Comparison Between Child-Pugh and Albumin-Bilirubin Scores</brief_title>
  <official_title>A Comparison Between Child-Pugh and Albumin-Bilirubin Scores in Patients With Spontaneous Rupture of Hepatocellular Carcinoma: A Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of
      hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare Child-Pugh and Albumin-Bilirubin scores in patients with spontaneous rupture of
      hepatocellular carcinoma. And to determine which is better in predicting long-term survival
      and short-term survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">August 1, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival of all patients</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival of all patients among different Child-Pugh and albumin-bilirubin scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term mortality of all patients</measure>
    <time_frame>Ninety days</time_frame>
    <description>Ninety-day mortality of all patients among different Child-Pugh and albumin-bilirubin scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term mortality of surgical subgroup</measure>
    <time_frame>Ninety days</time_frame>
    <description>Ninety-day mortality of the surgical subgroup among different Child-Pugh and albumin-bilirubin scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term mortality of non-surgical subgroup</measure>
    <time_frame>Ninety days</time_frame>
    <description>Ninety-day mortality of the non-surgical subgroup among different Child-Pugh and albumin-bilirubin scores</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">230</enrollment>
  <condition>Rupture, Spontaneous</condition>
  <condition>Rupture Liver</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Surgical treatment</arm_group_label>
    <description>Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical treatment</arm_group_label>
    <description>Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection</intervention_name>
    <description>Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.</description>
    <arm_group_label>Surgical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transcatheter arterial embolization</intervention_name>
    <description>Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.</description>
    <arm_group_label>Non-surgical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        From January 2005 to August 2015, all patients complied with the criteria mentioned above
        who received surgical treatment or non-surgical treatment at the investigator's center were
        included in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be diagnosed as hepatocellular carcinoma pathologically; had a tumor rupture confirmed
             by Intraperitoneal exploration or clinical signs and symptoms in combination with
             imaging examination.

        Exclusion Criteria:

          -  Be diagnosed as not hepatocellular carcinoma pathologicallyï¼›had repeated transcatheter
             arterial chemoembolization(TACE) or a long history (more than 1 year) of cancer
             treatment; loss of follow up or without complete data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-ping Chen, Prof. PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xiaoping Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Spontaneous rupture</keyword>
  <keyword>survival</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>Child-Pugh</keyword>
  <keyword>Albumin-bilirubin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Rupture</mesh_term>
    <mesh_term>Rupture, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bilirubin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

